Menopause and Cardiovascular Risk

Anichkov, D. A.; Шостак, Н. А.; Zhuravleva, A. D.

doi:10.20996/1819-6446-2005-1-1-37-42

Cited by 6 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Однако после наступления менопаузы показатели смертности от ССЗ у женщин увеличиваются, и становятся аналогичными показателям у мужчин [8,18]. Если распространенность ССЗ в репродуктивном периоде составляет 8%, то в климактерическом уже 53%, при этом риск развития АГ увеличивается в 2 раза, ИБС в 3 раза, а инсульта в 7 раз [8,19]. С каждым последующим десятилетием жизни частота смерти женщин от ССЗ возрастает в 3-5 раз.…”

Section: климактерический (менопаузальный) периоддефиниция проявлениunclassified

Hypertension and menopause

Остроумова

Васильевна

2019

Cardiovasc Ther Prev

View full text Add to dashboard Cite

The climacteric period (menopause) is one of the most important periods in a woman's life, reflecting the natural extinction of the reproductive function. Current hormonal changes and developing menopausal disorders initiate the formation of pathological conditions that have a negative impact on both the health and expectancy of life and its quality. Cardiovascular diseases are one of the most common pathological conditions. Arterial hypertension (AH) is a key risk factor for the development of cardiovascular diseases, in different periods of menopause has various clinical and pathogenetic features that must be considered during treatment. Indapamide have pronounced antihypertensive effect, organprotective properties and metabolic neutrality. It is drug of choice for mono or combination therapy for women with hypertension during different periods of menopause. Effective antihypertensive and organprotective action, metabolic neutrality and safety of nitrendipine use allow us to recommend this drug for combination therapy of hypertension in women in distant menopause. The combination of indapamide and nitrendipine may be one of the most effective tools for hypertension treating in women in distant climacteric period.

show abstract

Section: климактерический (менопаузальный) периоддефиниция проявлениunclassified

Hypertension and menopause

Остроумова

Васильевна

2019

Cardiovasc Ther Prev

View full text Add to dashboard Cite

show abstract

Cardiorenal disturbances in perimenopausal women

Tolstov

Мычка

Салов

et al. 2012

Cardiovasc Ther Prev

View full text Add to dashboard Cite

Aim. To identify early signs of renal dysfunction; to investigate the associations between renal function and vascular remodelling; to evaluate the role of metabolic and hydrodynamic disturbances in the development of cardiorenal syndrome among perimenopausal women; and to assess the potential of hormone replacement therapy (17β-estradiol 1 mg and drospirenone 2 mg) for the correction of the above-mentioned disturbances. Material and methods. In total, 69 perimenopausal women were divided into two groups. Group I included 69 premenopausal women, while Group II consisted of 43 women in early postmenopause. Mean age in Group I was 49,0 years (95% CI 48,0-51,0 years); in Group II, it was 54,0 (50,0-56,0) years (p<0,01). Age at menopause reached 50,3 (48,0-52,0) years, with median duration of menopause of 3,5 (2,0-5,0) years. All participants underwent biochemical blood tests (creatinine (Cr), uric acid (UA), lipid profile, and glucose tolerance test (GTT)). Large elastic artery remodelling was assessed by intima-media thickness (IMT) of common carotid artery (CCA). Non-invasive assessment of endothelial vasoregulatory function involved the measurement of brachial artery (BA) endothelium-dependent vasodilatation (EDVD) in the reactive hyperemia test (RHT). Renal function was assessed by glomerular filtration rate (GFR) and Cr clearance (CrC). Monoalbuminuria (MAU) was qualitatively assessed with a urine strip test. Postmenopausal women were additionally divided into two groups: 23 patients were administered HRT (17β-estradiol 1 mg and drospirenone 2 mg; Angelique medication), while 20 women not receiving HRT comprised a control group. At the end of the study, after 12 months, the assessment of metabolic status, body mass dynamics, endothelial vasoregulatory function, and CCA IMT was repeated. Results. In most postmenopausal women, lipid and carbohydrate metabolism disturbances were observed, which were typical for metabolic syndrome (MS). Lipid metabolism disturbances were observed as early as in premenopause, but reached their maximum during early postmenopause. Postmenopausal women, compared to their peers in premenopause, had significantly higher fasting and postprandial levels of blood glucose. Structural and functional changes in vascular wall were more severe in postmenopausal vs. premenopausal women (p<0,001). While blood flow velocity in the RHT was comparable in both groups, postmenopausal women did not demonstrate a comparable increase in BA EDVD, in contrast to premenopausal females. This could point to the decrease in BA sensitivity to endothelial shear stress among women in postmenopause. Reduced GFR was observed only in postmenopausal women. MAU was registered in premenopausal women with normal GFR, as well as in postmenopausal females. These data on independent role of MAU and reduced GFR suggest an increase in the proportion of women with subclinical renal injury, as a manifestation of target organ damage. Conclusion. The associations between vascular structure and function, renal function, and main MS components were demonstrated. HRT (17β-estradiol 1 mg and drospirenone 2 mg) had beneficial effects on BP dynamics, visceral obesity, metabolic status, and arterial structure and function.

show abstract

Effective strategies for the treatment of hypertension in postmenopausal obese women (case study)

Остроумова¹,

Васильевна²

2020

Profil. med.

View full text Add to dashboard Cite

Menopause and Cardiovascular Risk

Cited by 6 publications

References 0 publications

Hypertension and menopause

Hypertension and menopause

Cardiorenal disturbances in perimenopausal women

Effective strategies for the treatment of hypertension in postmenopausal obese women (case study)

Contact Info

Product

Resources

About